Oncotarget

Priority Research Papers:

Identification of a p53-repressed gene module in breast cancer cells

Takafumi Miyamoto, Chizu Tanikawa, Varalee Yodsurang, Yao-Zhong Zhang, Seiya Imoto, Rui Yamaguchi, Satoru Miyano, Hidewaki Nakagawa and Koichi Matsuda _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:55821-55836. https://doi.org/10.18632/oncotarget.19608

Metrics: PDF 2696 views  |   HTML 3634 views  |   ?  


Abstract

Takafumi Miyamoto1, Chizu Tanikawa1, Varalee Yodsurang5, Yao-Zhong Zhang2, Seiya Imoto3, Rui Yamaguchi2, Satoru Miyano2, Hidewaki Nakagawa4 and Koichi Matsuda5

1 Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

2 Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

3 Division of Health Medical Data Science, Health Intelligence Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan

4 Laboratory for Genome Sequencing Analysis, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan

5 Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan

Correspondence to:

Koichi Matsuda, email:

Keywords: p53, breast cancer, transcriptome analysis, adriamycin, gene module

Received: January 27, 2017 Accepted: May 28, 2017 Published: July 26, 2017

Abstract

The p53 protein is a sophisticated transcription factor that regulates dozens of target genes simultaneously in accordance with the cellular circumstances. Although considerable efforts have been made to elucidate the functions of p53-induced genes, a holistic understanding of the orchestrated signaling network repressed by p53 remains elusive. Here, we performed a systematic analysis to identify simultaneously regulated p53-repressed genes in breast cancer cells. Consequently, 28 genes were designated as the p53-repressed gene module, whose gene components were simultaneously suppressed in breast cancer cells treated with Adriamycin. A ChIP-seq database showed that p53 does not preferably bind to the region around the transcription start site of the p53-repressed gene module elements compared with that of p53-induced genes. Furthermore, we demonstrated that p21/CDKN1A plays a pivotal role in the suppression of the p53-repressed gene module in breast cancer cells. Finally, we showed that appropriate suppression of some genes belonging to the p53-repressed gene module contributed to a better prognosis of breast cancer patients. Taken together, these findings disentangle the gene regulatory network underlying the built-in p53-mediated tumor suppression system.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19608